Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)

NCT04938609 is registered in ClinicalTrials.gov with Providence Health & Services as lead sponsor.

NCT NCT04938609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04938609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)
Lead sponsor
Providence Health & Services
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 11, 2022
Completion date
January 11, 2031
Enrollment
28 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, head and neck squamous cell carcinoma